Ana S. C. Valdeira

Ana S. C. Valdeira

Auto-generated profile, based on publicly available information

Ana S. C. Valdeira

Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Jorge A. R. SalvadorJorge A. R. Salvador
Jorge A. R. Salvador
ALAna Sofia Mendes Leal
Ana Sofia Mendes Leal
AVAna S. Valdeira
Ana S. Valdeira
BGBruno Gonçalves
Bruno Gonçalves
DADaniela Alho
Daniela Alho
VMVanessa I.S. Mendes
Vanessa I.S. Mendes

1 January 2014
Verified
Book Chapter
Closed access
Jorge A. R. SalvadorJorge A. R. Salvador
Jorge A. R. Salvador
ALAna Sofia Mendes Leal
Ana Sofia Mendes Leal
DADaniela Alho
Daniela Alho
BGBruno Gonçalves
Bruno Gonçalves
AVAna S Valdeira
Ana S Valdeira
YJYongkui Jing
Yongkui Jing

25 July 2019 in Journal of Natural Products
Verified
Journal Article
Closed access
AVAna S. C. Valdeira
Ana S. C. Valdeira
EDEmad Darvishi
Emad Darvishi
GWGirma M. Woldemichael
Girma M. Woldemichael
John BeutlerJohn Beutler
John Beutler
Kirk GustafsonKirk Gustafson
Kirk Gustafson
Jorge A. R. SalvadorJorge A. R. Salvador
Jorge A. R. Salvador

28 September 2018 in Frontiers in Chemistry
Verified
Journal Article
Open access
PDF file
AVAna S. C. Valdeira
Ana S. C. Valdeira
DRDaniel A. Ritt
Daniel A. Ritt
DMDeborah K. Morrison
Deborah K. Morrison
JMJames B. McMahon
James B. McMahon
Kirk GustafsonKirk Gustafson
Kirk Gustafson
Jorge A. R. SalvadorJorge A. R. Salvador
Jorge A. R. Salvador
In the present study, a series of novel madecassic acid derivatives was synthesized and screened against the National Cancer Institute's 60 human cancer cell line panel. Among them, compounds 5, 12, and 17 displayed potent and highly differential antiproliferative activity against 80% of the tumor cells harboring the B-RafV600E mutation within the nanomolar range. Structure-activity analysis revealed that a 5-membered A ring containing an α,β-unsaturated aldehyde substituted at C-23 with a 2-furoyl group seems to be crucial to produce this particular growth inhibition signature. In silico analysis of the cytotoxicity pattern of these compounds identified two highly correlated clinically approved drugs with known B-RafV600E inhibitory activity. Follow-up analysis revealed inhibition of the ERK signaling pathway through the reduction of cellular Raf protein levels is a key mechanism of action of these compounds. In particular, 17 was the most potent compound in suppressing tumor growth of B-RafV600E-mutant cell lines and displayed the highest reduction of Raf protein levels among the tested compounds. Taken together, this study revealed that modifications of madecassic acid structure can provide molecules with potent anticancer activity against cell lines harboring the clinically relevant B-RafV600E mutation, with compound 17 identified as a promising lead for the development of new anticancer drugs.